New Bowel Disease Drug Shows 40% Remission Rate in Trial

A breakthrough treatment for ulcerative colitis brought 40% of patients into remission after just 12 weeks, offering fresh hope for millions living with inflammatory bowel disease.

Spyre Therapeutics' experimental drug succeeded in its first major trial, setting up competition with pharmaceutical giants to deliver better digestive disease treatments.